背景:COVID-19大流行已采取多种形式并继续演变,现在围绕着Omicron波,引起全球关注。随着COVID-19被宣布不再是国际关注的突发公共卫生事件(PHEIC),“COVID大流行还远远没有结束,自2023年1月以来,新的Omicron亚变体引起了人们的关注和关注。主要是XBB.1.5和XBB.1.16子变体,大流行仍然非常“活着”和“呼吸”。\"
方法:这篇综述包括关于COVIDOmicron峰的当前状态的五个高度关注的问题。我们搜索了四个主要的在线数据库来回答前四个问题。最后一个,我们对文献进行了系统的回顾,带有关键字\"Omicron,\"\"指南,\"和\"建议。\"
结果:共纳入31篇。当前Omicron波的主要症状包括典型的高烧,咳嗽,结膜炎(眼睛瘙痒),喉咙痛,流鼻涕,拥塞,疲劳,身体疼痛,和头痛。症状的中位潜伏期比以前的峰值短。针对COVID的疫苗接种仍然可以被认为对新的亚变体有效。
结论:指南建议继续采取个人保护措施,第三和第四剂量的助推器,以及二价信使RNA疫苗增强剂的施用。一致的抗病毒治疗是使用Nirmatrelvir和Ritonavir的联合治疗,暴露前预防的共识是Tixagevimab和Cilgavimab联合使用。我们希望本文提高人们对COVID持续存在的认识,以及降低风险的方法,特别是对于高危人群。
BACKGROUND: The COVID-19 pandemic has taken many forms and continues to evolve, now around the Omicron wave, raising concerns over the globe. With COVID-19 being declared no longer a \"public health emergency of international concern (PHEIC),\" the COVID pandemic is still far from over, as new Omicron subvariants of interest and concern have risen since January of 2023. Mainly with the XBB.1.5 and XBB.1.16 subvariants, the pandemic is still very much \"alive\" and \"breathing.\"
METHODS: This review consists of five highly concerning questions about the current state of the COVID Omicron peak. We searched four main online databases to answer the first four questions. For the last one, we performed a systematic review of the literature, with keywords \"Omicron,\" \"Guidelines,\" and \"Recommendations.\"
RESULTS: A total of 31 articles were included. The main symptoms of the current Omicron wave include a characteristically high fever, coughing, conjunctivitis (with itching eyes), sore throat, runny nose, congestion, fatigue, body ache, and headache. The median incubation period of the symptoms is shorter than the previous peaks. Vaccination against COVID can still be considered effective for the new subvariants.
CONCLUSIONS: Guidelines recommend continuation of personal protective measures, third and fourth dose boosters, along with administration of bivalent messenger RNA vaccine boosters. The consensus antiviral treatment is combination therapy using
Nirmatrelvir and Ritonavir, and the consensus for pre-exposure prophylaxis is Tixagevimab and Cilgavimab combination. We hope the present paper raises awareness for the continuing presence of COVID and ways to lower the risks, especially for at-risk groups.